Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636882 · ClinicalTrials.gov registry record · Phase 2
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
A Phase 2 study, sponsored by Viralytics.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01636882 is a Phase 2 study that has completed, run by Viralytics. The registered enrollment target is 16 participants.
The verdict
NCT01636882, a Phase 2 study, has completed, sponsored by Viralytics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment. In order to accommodate those patients further treatment to complete 48 weeks of CVA21 intratumoral injections will be made available.
Interventions
- BIOLOGICAL CVA21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-07-03 |
| Est. Completion | 2016-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01636882
The ClinicalTrials.gov registry entry for NCT01636882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viralytics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CVA21 is the first listed.
NCT01636882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01636882 about?
NCT01636882 is a clinical study titled "CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)". This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment. In order to accommodate those patients further treatment to complete 48 weeks of CVA21 i...
What is the current status of trial NCT01636882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2012-07-03. Estimated completion is 2016-04-06.
What interventions are being tested in trial NCT01636882?
The interventions under investigation include: CVA21 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01636882?
This trial is sponsored by Viralytics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.